Delivery Order SPE2DB22D1017-SPE2DB24FG2CD

Award Date 7/29/24
Potential Completion Date 7/30/24
Potential Value $6.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a $4,006.46 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for delivering a wide range of medical commodities to support military treatment programs and facilities worldwide. The contract has no set-aside...
The U.S. Defense Logistics Agency (DLA) awarded a $3,156.00 delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of MOUNJARO 15 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to support military treatment facilities and other federal healthcare programs. This award is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order contract to AmerisourceBergen Drug Corp in the amount of $8,763.54 for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of medical commodities to support...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $1,052.00 to the prime contractor, AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the provision of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to support military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $18,665.10 delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of MOUNJARO 2.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, and has a completion date of November 6, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which provides a...
The Defense Logistics Agency (DLA) awarded a $1,578.00 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. Under this IDC, Amerisourcebergen supplies a wide range of pharmaceutical products and medical supplies to support the...
This is a $6,032.86 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MOUNJARO 10 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of January 8, 2025. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,026.03 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distribution company. The contract is for the supply of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, with a period of performance through July 15, 2024. This delivery order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $7,890.00 to AmerisourceBergen Drug Corp, a for-profit pharmaceutical distribution company, for the supply of MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00, to provide a comprehensive range of pharmaceuticals and medical supplies to DLA Troop Support Medical...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $1,578.00 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML pharmaceuticals. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded by DLA to Amerisourcebergen Drug Corp as the sole awardee, which serves as the primary contract vehicle for the company to deliver...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB24FG2CD
    Delivery Order

The Defense Logistics Agency (DLA) awarded a $6,914.92 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of MOUNJARO 10 MG/0.5 ML PEN 0.5ML. This order was placed under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has a completion date of July 30, 2024 and does not utilize any set-aside designation.

Generated 10/28/24, 9:49 AM